Dr. Timothy Moore, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 428
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of Pittsburgh School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35067263 -
Hospice and Palliative Medicine (Internal Medicine) Physician
OH license 35067263
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Carmel East & West Columbus, OH
- Mount Carmel St Ann's Westerville, OH
Medical groups
- American Oncology PArtners PA (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 428
- Services billed
- 55,610
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,712 | 53 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 857 | 290 |
| Established patient office or other outpatient visit, 30-39 minutes | 477 | 240 |
| Injection, dexamethasone sodium phosphate, 1 mg | 260 | 12 |
| Insertion of needle into vein for collection of blood sample | 224 | 140 |
| Established patient office or other outpatient visit, 20-29 minutes | 197 | 158 |
| Injection of drug or substance under skin or into muscle | 195 | 29 |
| Administration of chemotherapy into vein, 1 hour or less | 91 | 29 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 90 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 78 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Columbus, OH | 94 |
| Revlimid (lenalidomide) | 81 |
| Oxycodone Hcl Other prescribers in Columbus, OH | 66 |
| Tamoxifen Citrate Other prescribers in Columbus, OH | 53 |
| Letrozole Other prescribers in Columbus, OH | 49 |
| Prochlorperazine Maleate Other prescribers in Columbus, OH | 47 |
| Brukinsa (zanubrutinib) | 44 |
| Acyclovir Other prescribers in Columbus, OH | 41 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Columbus, OH | 37 |
| Dexamethasone Other prescribers in Columbus, OH | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 28 payments worth $3,671 in total to this clinician.
| Pfizer Inc. | $1,369 |
|---|---|
| Caris Mpi, Inc. | $1,044 |
| Geron Corporation | $780 |
| Aveo Pharmaceuticals, Inc. | $138 |
| AbbVie Inc. | $82.76 |
| Eisai Inc. | $77.68 |
| Array Biopharma Inc | $60.22 |
| E.r. Squibb & Sons, L.l.c. | $51.87 |
| Consulting Fee | $2,980 |
|---|---|
| Food and Beverage | $691 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 20, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,300 |
| Caris Mpi, Inc. Sep 5, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $900 |
| Geron Corporation Jun 20, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $780 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $35,981 in research payments for these studies, mostly to the institutions running them.
- Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.